News

Presentations to include initial findings with Company's mirvetuximab soravtansine (IMGN853) for ovarian cancer and results from Roche's MARIANNE trial with Kadcyla^®

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today provided information on ImmunoGen-related presentations to take place at the 2015 American Society of Clinical Oncology (ASCO) annual meeting being held May 29-June 2 in Chicago, IL.

ImmunoGen's mirvetuximab soravtansine is the first ADC to target folate receptor alpha (FRα), which is highly expressed on many ovarian cancers and on other types of solid tumors. The ASCO presentations will be on the initial findings from the Phase I expansion cohort assessing this ADC as a single agent for the treatment of patients with FRα-positive platinum-resistant ovarian cancer (abstract #5518) and the dose-finding results to date with a weekly dosing schedule compared with a once every three week schedule (abstract #5558).

Abstract #5518

• Title: "Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial."
• Gynecologic Cancer Poster Session: May 30, 1:15-4:45pm CT (S Hall A, Board #76), followed by oral discussion with highlights during the Gynecologic Cancer Poster Discussion Session 4:45-6:00pm CT (E354b).

Abstract #5558

• Title: "Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors."
• Gynecologic Cancer Poster Session: May 30, 1:15-4:45pm CT (S Hall A, Board #116)

There will be several presentations on Roche's Kadcyla^® (ado-trastuzumab emtansine), which uses ImmunoGen's ADC technology, including one on the data from the MARIANNE Phase III trial (Abstract #507).

• Title: "Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study."
• Breast Cancer Oral Abstract Session: June 1, 10:12-10:24am CT (N Hall B1)

Additional information can be found on the 2015 ASCO annual meeting website.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche's Kadcyla^® is the first marketed product with ImmunoGen's ADC technology. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.

For Investors:

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media